ONC vs. PLI, ABCN, EMC, FRX, BCT, IPA, SCYB, COM, MDNA, and NVH
Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Medicenna Therapeutics (MDNA), and Novoheart (NVH). These companies are all part of the "biotechnology" industry.
Oncolytics Biotech vs.
ProMetic Life Sciences (TSE:PLI) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
1.8% of Oncolytics Biotech shares are owned by institutional investors. 3.8% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, ProMetic Life Sciences' average media sentiment score of 0.00 beat Oncolytics Biotech's score of -1.32 indicating that ProMetic Life Sciences is being referred to more favorably in the media.
Oncolytics Biotech has lower revenue, but higher earnings than ProMetic Life Sciences. Oncolytics Biotech is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.
ProMetic Life Sciences' return on equity of 0.00% beat Oncolytics Biotech's return on equity.
ProMetic Life Sciences received 246 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. However, 74.81% of users gave Oncolytics Biotech an outperform vote while only 67.69% of users gave ProMetic Life Sciences an outperform vote.
Summary
ProMetic Life Sciences beats Oncolytics Biotech on 6 of the 11 factors compared between the two stocks.
Get Oncolytics Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncolytics Biotech Competitors List
Related Companies and Tools
This page (TSE:ONC) was last updated on 2/22/2025 by MarketBeat.com Staff
